HGBCL

EPCORITAMAB RECEIVES FDA APPROVAL FOR RELAPSED/REFRACTORY DLBCL

SG Tylor

The FDA has granted approval to epcoritamab-bysp (Epkinly), the first T-cellā€“engaging bispecific antibody, for the treatment of relapsed/refractory diffuse large ...